

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virgina 22313-1450 www.spile.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/755,826	01/04/2001	Charles W. Pearce	PEARCE 26	5388
473% 7590 09/02/2010 HITT GAINES, PC LSI Corporation PO BOX 832570			EXAMINER	
			CHEN, JACK S J	
RICHARDSO			ART UNIT	PAPER NUMBER
			2893	
			NOTIFICATION DATE	DELIVERY MODE
			09/02/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docket@hittgaines.com

Application No. Applicant(s) 09/755.826 PEARCE, CHARLES W. Office Action Summary Examiner Art Unit Jack Chen 2893 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 01 June 2010. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-3.5-9.11-13.15-18 and 20-24 is/are pending in the application. 4a) Of the above claim(s) 11-13.15-18.20 and 22-24 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-3, 5-9, 21 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) ____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner, Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)

Paper No(s)/Mail Date

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (FTO/95/68)

Paper No(s)/Mail Date. _

6) Other:

51 Notice of Informal Patent Application

Application/Control Number: 09/755,826 Page 2

Art Unit: 2893

DETAILED ACTION

In view of the appeal brief filed on June 01, 2010, PROSECUTION IS HEREBY

REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two ontions:

(1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37

CFR 1.113 (if this Office action is final); or,

(2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an

appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee

can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have

been increased since they were previously paid, then appellant must pay the difference between

the increased fees and the amount previously paid.

A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing

below:

/Davienne Monbleau/

Supervisory Patent Examiner, Art Unit 2893

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. Application/Control Number: 09/755,826

Art Unit: 2893

 Claims 1-2, 5, 8 and 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Bassous et al., US/4,173.818.

Re claim 1, Bassous et al. disclose a method of manufacturing a laterally diffused metal oxide semiconductor (LDMOS) device (see the figs. 1A-1F disclosure, for example), comprising: forming first 12 and second 12 isolation structures within a substrate 10 (fig. 1A); forming a lightly-doped source/drain region 16 between the first 12 and second 12 isolation structures (fig. 1A) with only a first dopant (i.e., phosphorus) and without the use of a mask layer between the first and second isolation structures (fig. 1A); and creating a gate 20 (fig. 1F) over the lightly-doped source/drain region, also see figs. 1A-2G and cols. 1-10 for more details.

Re claim 2, wherein forming includes forming a lightly-doped source/drain region with a first N-type dopant (col. 4, lines 54-56 for example).

Re claim 5, further including diffusing a second dopant at least partially across the lightly-doped source/drain region 16 and under the gate 20 to form a first portion of a channel 34 (see the fig. 1E disclosure).

Re claim 8, further including placing a heavy concentration of the first dopant in a region 28 adjacent a source side of the gate 20, and in the lightly-doped source/drain region 16 (at region 30) adjacent a drain side of the gate (see the fig. 1C disclosure).

Re claim 21, wherein forming the lightly-doped source/drain region 16 includes forming the lightly-doped source/drain region using a blanket implant process over the entire substrate (see the fig. 1A disclosure).

Claim Rejections - 35 USC § 103

- The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all
 obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- Claims 3, 6-7 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bassous et al., US/4,173,818.

Bassous et al. disclosed in above; however, Bassous et al. are silent to the implanting dosage as recited in the instant claims 3, 6-7 and the claimed distance as recited in claim 9.

The implanting dosage/concentration range of claims 3, 6-7 and the claimed distance range of claim 9 are considered to involve routine optimization while has been held to be within the level of ordinary skill in the art. As noted in In re Aller, the selection of reaction parameters such as temperature and concentration would have been obvious:

"Normally, it is to be expected that a change in temperature, or in concentration, or in both, would be an unpatentable modification. Under some circumstances, however, changes such as these may impart patentability to a process if the particular ranges claimed produce a new and unexpected result which is different in kind and not merely

Application/Control Number: 09/755,826

Art Unit: 2893

degree from the results of the prior art...such ranges are termed Acritical ranges and the applicant has the burden of proving such criticality.... More particularly, where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."

In re Aller 105 USPQ233, 255 (CCPA 1955). See also In re Waite 77 USPQ 586 (CCPA 1948); In re Scherl 70 USPQ 204 (CCPA 1946); In re Irmscher 66 USPQ 314 (CCPA 1945); In re Norman 66 USPQ 308 (CCPA 1945); In re Swenson 56 USPQ 372 (CCPA 1942); In re Sola 25 USPQ 433 (CCPA 1935); In re Dreyfus 24 USPQ 52 (CCPA 1934).

Therefore, one of ordinary skill in the requisite art at the time the invention was made would have used any dosage/concentration range and/or distance range suitable to the method in process of Bassous et al. in order to optimize the process.

Furthermore, the specification contains no disclosure of either the critical nature of the claimed process (i.e. –the claimed dosage and/or distance ranges) or any unexpected results arising therefrom. Where patentability is said to be based upon particular chosen limitations or upon another variable recited in a claim, the Applicant must show that the chosen limitations are critical. *In re Woodruff*, 919 F.2d 1575, 1578 (Fed. Cir. 1990).

Art Unit: 2893

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jack Chen whose telephone number is (571)272-1689. The examiner can normally be reached on Monday-Friday (8:00am-4:30pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Davienne N. Monbleau can be reached on (571)272-1945. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jack Chen Primary Examiner Art Unit 2893

/Jack Chen/ Primary Examiner, Art Unit 2893

/Davienne Monbleau/ Supervisory Patent Examiner, Art Unit 2893